Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce a non-brokered private placement (the " Offering ") of up to 16,666,667 units in the capital of the Company (the " Units ") at a price of $0.03 per Unit for gross proceeds of up to $500,000. Each Unit consists of one (1) common share of... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces that further to its news release dated January 24, 2025, the Company has received an extension from The CSE (the "CSE") to close its non-brokered private placement of up to 10,000,000 units of the Company (the "Units") at a price of CDN$0.03c per Unit... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology. PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical" ) a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products is pleased to announce that is has appointed Dr. Bryan Jones ("Bryan") as an advisor to the Company as Director of... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce a non-brokered private placement (the " Offering ") of up to 10,000,000 units in the capital of the Company (the " Units ") at a price of $0.03 per Unit for gross proceeds of up to $300,000. Each Unit consists of one (1) common share of... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. today announced its... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical "), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024. PreveCeutical's board of... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Patroski J.... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Barry... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc . (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Deepak... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. announce the appointments of... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 15, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that, further to its news release dated October 30, 2024, PreveCeutical has closed the... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly-owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Mariya... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has signed a definitive agreement on the 29 October, 2024 (the " Agreement ") to... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has engaged Toronto-based Phoenix Corporate Finance Inc. (" Phoenix ") as its... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces that it has entered into a Marketing Service Agreement dated effective September 1, 2024 (the " Agreement ") with Outside the Box Capital Ltd. (" OTB "), whereby OTB will provide the Company with certain marketing services (the " Services "). As... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is pleased to announce that, further to the Company's news release dated June 28, 2024, the Company has completed the filings of its interim financial statements, accompanying management's discussion and analysis and related CEO and CFO certificates for the... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is pleased to announce that today it has filed its audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the " Annual... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that it has entered into a series of unsecured, non-convertible and interest-free loan agreements with, the Company's Chief Executive Officer, interim Chief Financial Officer and Chair, Stephen Van Deventer, and the Company's former President and... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is providing an update with respect to the Management Cease Trade Order (" MCTO ") issued by the British Columbia Securities Commission (the " BCSC ") under National Policy 12-203 - Management Cease Trade Orders (" NP 12-203 "), effective as of May 2, 2024,... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces that it, along with certain others, filed a Notice of Civil Claim (the " Claim ") in the British Columbia Supreme Court on June 5, 2024 against its former legal counsel (the " Defendants "). The Claim alleges that the Defendants were negligent in the... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is providing an update with respect to the Management Cease Trade Order (" MCTO ") issued by the British Columbia Securities Commission (the " BCSC ") under National Policy 12-203 - Management Cease Trade Orders (" NP 12-203 "), effective as of May 2, 2024, and... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is pleased to announce that further to its news release dated May 16, 2024, the Company has closed the first tranche of its non-brokered private placement (the "Private Placement" ) for gross proceeds of $115,000 through the sale of 4,600,000 units of the... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is providing an update with respect to the Management Cease Trade Order (" MCTO ") issued by the British Columbia Securities Commission (the " BCSC ") under National Policy 12-203 - Management Cease Trade Orders (" NP 12-203 "), effective as of May 2, 2024, and... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended... Read More

VANCOUVER, BC , Dec. 4, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US... Read More

VANCOUVER, BC , Sept. 18, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this... Read More

VANCOUVER, BC , Sept. 12, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology. The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of... Read More

VANCOUVER, BC , July 24, 2023 /CNW/ - PreveCeutica l Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information. PreveCeutical plans to use this... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A forum on April 25, 2023. All participants are encouraged to pre-register to ensure access to the live virtual event and to submit any questions... Read More

Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria, KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844H PreveCeutical's Pain Management Peptides Program Published in the Swiss Medical Journal. Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023 , to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective February 17, 2023. Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ( "Endosane") , a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of... Read More